New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
09:18 EDTATHX, ABX, FURX, PFE, ETP, HAE, GLW, NEM, SOHU, SUSS, OGXI, YOKU, FRX, BAC, AGEN, POZN, AZNOn The Fly: Pre-market Movers
HIGHER: AstraZeneca (AZN), up 16% after Pfizer (PFE) confirms takeover offer made and turned down by company. Pfizer shares are also up 2.7% as the company says it is still interested in a potential AstraZeneca combination and is weighing its next steps... Furiex (FURX), up 31% after agreeing to be acquired by Forest labs (FRX) for $95 per share and contingent future payments... Susser (SUSS), up 37% after agreeing to be acquired by Energy Transfer Partners (ETP) for approx. $1.8B... Agenus (AGEN), up 10% after announcing collaboration and license agreement with Merck (MRK)... Yokou Toudou (YOKU), up 10% after announcing $1.22B investment led by Alibaba... Corning (GLW), up 2.7% after earnings report. DOWN AFTER EARNINGS: Sohu.com (SOHU), down 6.6%... Haemonetics (HAE), down 9.5%... ALSO LOWER: Bank of America (BAC), down 2.6% after suspending capital actions, including repurchase authorization... Newmont Mining (NEM), down 5.7% after terminating merger discussions with Barrick Gold (ABX)... Athersys (ATHX), down 56% after MultiStem therapy trial fails to show meaningful benefit... OncoGenex (OGXI), down 52% after Synergy did not meet primary endpoint in Phase 3 trial... POZEN (POZN), down 12% after drug candidates PA8140/PA32540 receive Complete Response Letter from FDA.
News For AZN;PFE;BAC;SOHU;FURX;FRX;NEM;ABX;YOKU;GLW;ATHX;OGXI;HAE;POZN;SUSS;ETP;AGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
November 14, 2014
09:24 EDTYOKUYouku Tudou downgraded to Underweight from Neutral at HSBC
09:16 EDTYOKUOn The Fly: Pre-market Movers
Subscribe for More Information
07:14 EDTAZN, PFEAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
17:13 EDTYOKUYouku Tudou sees Q4 revenue RMB1.15B-RMB1.22B, consensus RMB1.21B
Subscribe for More Information
17:10 EDTYOKUYouku Tudou reports Q3 adjusted EPS RMB(50c) , consensus RMB(82c)
Reports Q3 revenue RMB1.11B, consensus RMB1.10B.
15:18 EDTYOKUNotable companies reporting after market close
Subscribe for More Information
07:38 EDTPFEBloomberg Link to hold a conference
The Year Ahead: 2015 is being held in Washington, D.C. with a pre-conference dinner on November 13 followed by company presentations on November 14,
07:16 EDTAZNBIT Congress to hold a conference
Subscribe for More Information
07:03 EDTAZNAstraZeneca initiates development program for Brilinta reversal agent
Subscribe for More Information
05:34 EDTAZNAstraZeneca, Isis Pharmaceuticals to co-develop oligonucleotide delivery methods
Subscribe for More Information
November 12, 2014
16:23 EDTBACOn The Fly: Closing Wrap
Subscribe for More Information
12:38 EDTBACOn The Fly: Midday Wrap
Subscribe for More Information
11:17 EDTAZN, PFELeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
10:14 EDTBACOCC fines Bank of America, Citigroup, JPMorgan $950M over FX trading
Subscribe for More Information
08:51 EDTABXBarrick exec says Pascua Lama completion would cost another $4B, Reuters reports
Barrick Gold, which halted its Pascua Lama gold mine project last year after investing $5B, would like to find a path forward but believes the mine would likely cost another $4B to complete, Edmundo Flores, SVP of Pascua Lama, told financial newspaper Diario Financiero, according to Reuters. Reference Link
08:13 EDTPFEBoston Biotech to hold a conference
Subscribe for More Information
08:02 EDTPFECredit Suisse to hold a conference
Subscribe for More Information
07:35 EDTAZNAdvaxis submits IND application for ADXS-HPV Phase 1/2 study, MEDI4736
Advaxis (ADXS) announced that the company has submitted an Investigational New Drug application, or IND, to the FDA to conduct a Phase 1/2 study of ADXS-HPV alone or in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, for the treatment of advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. This follows the press release issued in July announcing the clinical trial collaboration between Advaxis and MedImmune, the global biologics research and development arm of AstraZeneca (AZN).
07:28 EDTBACBofA/Merrill to hold a conference
Subscribe for More Information
05:42 EDTYOKUYouku Tudou announces partnership with Xiaomi
Youku Tudou announced that it has entered into a strategic partnership with Xiaomi. The partnership aims to accelerate the development of its multi-screen media and entertainment ecosystem. The two companies will jointly develop content and technology, including developing multi-screen online video services. Xiaomi will invest in Youku Tudou by acquiring the latter's stock on the open market. It will also license content from Youku Tudou, and the two companies will jointly invest in the production and distribution of online video content and movies.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use